376 related articles for article (PubMed ID: 12698181)
1. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
Ulrich-Pur H; Raderer M; Verena Kornek G; Schüll B; Schmid K; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Scheithauer W
Br J Cancer; 2003 Apr; 88(8):1180-4. PubMed ID: 12698181
[TBL] [Abstract][Full Text] [Related]
2. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J
Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414
[TBL] [Abstract][Full Text] [Related]
3. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.
Scheithauer W; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Gedlicka C; Schüll B; Brugger S; Schneeweiss B; Lang F; Lenauer A; Depisch D
J Clin Oncol; 2002 Jan; 20(1):165-72. PubMed ID: 11773166
[TBL] [Abstract][Full Text] [Related]
4. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
Stathopoulos GP; Syrigos K; Aravantinos G; Polyzos A; Papakotoulas P; Fountzilas G; Potamianou A; Ziras N; Boukovinas J; Varthalitis J; Androulakis N; Kotsakis A; Samonis G; Georgoulias V
Br J Cancer; 2006 Sep; 95(5):587-92. PubMed ID: 16909140
[TBL] [Abstract][Full Text] [Related]
5. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
Neri B; Cipriani G; Grifoni R; Molinara E; Pantaleo P; Rangan S; Vannini A; Tonelli P; Valeri A; Pantalone D; Taddei A; Bechi P
Oncol Res; 2009; 17(11-12):559-64. PubMed ID: 19806786
[TBL] [Abstract][Full Text] [Related]
7. Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.
Van Laethem JL; Van Maele P; Verslype C; Polus M; Demols A; Houbiers G; Caenepeel P; Leleux A; Vermaut RR; Van Cutsem E; Peeters M
Oncology; 2004; 67(5-6):338-43. PubMed ID: 15713988
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
[TBL] [Abstract][Full Text] [Related]
9. Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Umemura A; Nitta H; Sasaki A; Takahara T; Hasegawa Y; Wakabayashi G
Hepatogastroenterology; 2014 May; 61(131):814-20. PubMed ID: 26176079
[TBL] [Abstract][Full Text] [Related]
10. Activity of raltitrexed and gemcitabine in advanced pancreatic cancer.
Kralidis E; Aebi S; Friess H; Büchler MW; Borner MM
Ann Oncol; 2003 Apr; 14(4):574-9. PubMed ID: 12649104
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma.
Ford HE; Cunningham D; Ross PJ; Rao S; Aherne GW; Benepal TS; Price T; Massey A; Vernillet L; Gruia G
Br J Cancer; 2000 Jul; 83(2):146-52. PubMed ID: 10901362
[TBL] [Abstract][Full Text] [Related]
12. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.
Ioka T; Komatsu Y; Mizuno N; Tsuji A; Ohkawa S; Tanaka M; Iguchi H; Ishiguro A; Kitano M; Satoh T; Yamaguchi T; Takeda K; Kida M; Eguchi K; Ito T; Munakata M; Itoi T; Furuse J; Hamada C; Sakata Y
Br J Cancer; 2017 Feb; 116(4):464-471. PubMed ID: 28081543
[TBL] [Abstract][Full Text] [Related]
13. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.
Feliu J; Castañón C; Salud A; Mel JR; Escudero P; Pelegrín A; López-Gómez L; Ruiz M; González E; Juárez F; Lizón J; Castro J; González-Barón M;
Br J Cancer; 2005 Nov; 93(11):1230-5. PubMed ID: 16265344
[TBL] [Abstract][Full Text] [Related]
14. Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Tsavaris N; Kosmas C; Vadiaka M; Koufos C
BMC Cancer; 2002; 2():2. PubMed ID: 11860608
[TBL] [Abstract][Full Text] [Related]
15. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
[TBL] [Abstract][Full Text] [Related]
16. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
[TBL] [Abstract][Full Text] [Related]
17. [Raltitrexed and oxaliplatin in colorectal cancer: in vitro and in vivo study of a synergistic cytostatic combination].
Schüll B; Scheithauer W
Acta Med Austriaca; 2002; 29(4):124-31. PubMed ID: 12424937
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
Rocha Lima CM; Green MR; Rotche R; Miller WH; Jeffrey GM; Cisar LA; Morganti A; Orlando N; Gruia G; Miller LL
J Clin Oncol; 2004 Sep; 22(18):3776-83. PubMed ID: 15365074
[TBL] [Abstract][Full Text] [Related]
19. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
